Thrombolysis and adjunctive therapies in acute myocardial infarction

被引：0
作者：
Helft, G
Worthley, SG
Zaman, AG
Samama, MM
Badimon, JJ
机构：
[1] Hop Necker Enfants Malad, Clin Cardiol Adultes, Assistance Publ, F-75015 Paris, France
[2] Mt Sinai Med Ctr, Cardiovasc Biol Res Lab, New York, NY 10029 USA
[3] Hop Hotel Dieu, Serv Hematol Biol, Assistance Publ, Paris, France
来源：
HAEMOSTASIS | 2000年 / 30卷 / 04期
关键词：
thrombolysis; myocardial infarction; GP IIb/IIIa inhibitors;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Thrombolysis and percutaneous transluminal angioplasty represent the cornerstone of the pharmacologic treatment of and the interventional approach to patients with myocardial infarction (MI). They are very effective. However, they are hampered by some critical limitations. Therefore, alternatives to standard thrombolytic therapy have been developed. Platelet glycoprotein (GP) IIb/IIIa blockade is under investigation and seems very attractive. This review will focus on the use of GP IIb/IIIa antagonists and thrombin inhibitors as adjunctive therapies to the thrombolytic treatment of patients with acute MI. Copyright (C) 2001 S. Karger AG, Basel.
引用
收藏
页码：159 / 167
页数：9
相关论文
共 46 条
[1]  
[Anonymous], 1995, Lancet, V346, P329
[2]   HIRUDIN IN ACUTE MYOCARDIAL-INFARCTION - SAFETY REPORT FROM THE THROMBOLYSIS AND THROMBIN INHIBITION IN MYOCARDIAL-INFARCTION (TIMI)-9A TRIAL [J].
ANTMAN, EM .
CIRCULATION, 1994, 90 (04) :1624-1630
[3]   Abciximab facilitates the rate and extent of thrombolysis - Results of the thrombolysis in myocardial infarction (TIMI) 14 trial [J].
Antman, EM ;
Giugliano, RP ;
Gibson, CM ;
McCabe, CH ;
Coussement, P ;
Kleiman, NS ;
Vahanian, A ;
Adgey, AAJ ;
Menown, I ;
Rupprecht, HJ ;
Van der Wieken, R ;
Ducas, J ;
Scherer, J ;
Anderson, K ;
Van de Werf, F ;
Braunwald, E .
CIRCULATION, 1999, 99 (21) :2720-2732
[4]  
Betriu A, 1997, NEW ENGL J MED, V336, P1621
[5]   A PILOT TRIAL OF RECOMBINANT DESULFATOHIRUDIN COMPARED WITH HEPARIN IN CONJUNCTION WITH TISSUE-TYPE PLASMINOGEN-ACTIVATOR AND ASPIRIN FOR ACUTE MYOCARDIAL-INFARCTION - RESULTS OF THE THROMBOLYSIS IN MYOCARDIAL-INFARCTION (TIMI)-5 TRIAL [J].
CANNON, CP ;
MCCABE, CH ;
HENRY, TD ;
SCHWEIGER, MJ ;
GIBSON, RS ;
MUELLER, HS ;
BECKER, RC ;
KLEIMAN, NS ;
HAUGLAND, JM ;
ANDERSON, JL ;
SHARAF, BL ;
EDWARDS, SJ ;
ROGERS, WJ ;
WILLIAMS, DO ;
BRAUNWALD, E .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, 23 (05) :993-1003
[6]  
CANNON CP, 1994, J THROMB THROMBOLYS, V1, P27
[7]   EVIDENCE FAVORING USE OF ANTICOAGULANTS IN HOSPITAL PHASE OF ACUTE MYOCARDIAL-INFARCTION [J].
CHALMERS, TC ;
MATTA, RJ ;
SMITH, H ;
KUNZLER, AM .
NEW ENGLAND JOURNAL OF MEDICINE, 1977, 297 (20) :1091-1096
[8]   Low molecular weight heparin as an adjunct to thrombolysis for acute myocardial infarction:: the FATIMA study [J].
Chamuleau, SAJ ;
de Winter, RJ ;
Levi, M ;
Adams, R ;
Büller, HR ;
Prins, MH ;
Lie, KI ;
Peters, RJG .
HEART, 1998, 80 (01) :35-39
[9]   The ESSENCE trial: Efficacy and safety of subcutaneous enoxaparin in unstable angina and non-Q-wave MI: A double-blind, randomized, parallel-group, multicenter study comparing enoxaparin and intravenous unfractionated heparin: Methods and design [J].
Cohen M. ;
Blaber R. ;
Demers C. ;
Gurfinkel E.P. ;
Langer A. ;
Fromell G. ;
Turpie A.G.G. ;
Premmereur J. .
Journal of Thrombosis and Thrombolysis, 1997, 4 (2) :271-274
[10]   PLATELETS AND THROMBOLYTIC THERAPY [J].
COLLER, BS .
NEW ENGLAND JOURNAL OF MEDICINE, 1990, 322 (01) :33-42
12345